Supportive measures for side effects of hormonal therapy on sexual activity in prostate cancer

Stephen Freedland, MD, Cedars-Sinai Medical Center, Los Angeles, CA, gives an overview of supportive measures used to mitigate the side effects of combination therapy (enzalutamide and leuprolide) on sexual activity in high-risk biochemically recurrent non-metastatic prostate cancer. Dr Freedland highlights the importance of shared decision making when starting treatment to offer patients an educated choice between this combination therapy and enzalutamide monotherapy, which has fewer side effects on erectile function. Additionally there are a variety of treatments for erectile dysfunction which can be offered to affected patients to mitigate this adverse effect and maintain their quality of life. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.